Interleukin‐ 28B: a prognostic marker in interferon based therapy of chronic HCV patients of the Pakistan with variable treatment response

Publisher： John Wiley & Sons Inc

E-ISSN： 1600-0463|123|9|765-771

ISSN： 0903-4641

Source： APMIS (ELECTRONIC), Vol.123, Iss.9, 2015-09, pp. : 765-771

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impaired induction of interleukin 28B and expression of interferon λ 4 associated with nonresponse to interferon‐based therapy in chronic hepatitis C

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 6, 2015-06 ,pp. : 1075-1084

John Wiley & Sons Inc

Access to resources Recommend Favorite

HLA‐DP, IL28B gene polymorphisms and IFN

By  

HEPATOLOGY RESEARCH, Vol. 44, Iss. 9, 2014-09 ,pp. : 1000-1007

John Wiley & Sons Inc

Access to resources Recommend Favorite

Genetic variant of IL28B rs12979860, as predictive marker of interferon‐based therapy in Pakistani population

By  

APMIS (ELECTRONIC), Vol. 123, Iss. 4, 2015-04 ,pp. : 342-349

John Wiley & Sons Inc

Access to resources Recommend Favorite

Autoantibodies to CD69 in Patients with Chronic Hepatitis Type C: A Candidate Marker for Predicting the Response to Interferon Therapy

By  

Intervirology, Vol. 46, Iss. 1, 2003-02 ,pp. : 56-65

Karger

Access to resources Recommend Favorite

A Literature Analysis of Prognostic Factors for Response and Quality of Response of Patients with Renal Cell Carcinoma to Interleukin-2-Based Therapy

By  

Oncology, Vol. 61, Iss. 2, 2001-08 ,pp. : 91-101

Karger

Access to resources Recommend Favorite